SNDX FY 2017 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+72.8% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$62M-2939.0% margin

Net Income

-$61M-2884.3% margin

EPS (Diluted)

$-2.90

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$137M

Total Liabilities

$33M

Stockholders' Equity

$104M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+72.8%
Gross Profit	$2M	$1M	+72.8%
Operating Income	-$62M	-$44M	-41.6%
Net Income	-$61M	-$44M	-36.7%